The price of Novavax, Inc. (NASDAQ:NVAX) shares last traded on Wall Street fell -0.48% to $6.24.
Based on available information, 6 analysts follow Novavax, Inc. (NASDAQ:NVAX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $5.00, we find $15.00. Given the previous closing price of $6.27, this indicates a potential upside of 139.23 percent. NVAX stock price is now -13.15% away from the 50-day moving average and -20.17% away from the 200-day moving average. The market capitalization of the company currently stands at $741.25M.
Among analysts, 1 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $20.20 as their price target over the next twelve months.
With the price target maintained at $15, B. Riley Securities recently Upgraded its rating from Neutral to Buy for Novavax, Inc. (NASDAQ: NVAX).
In other news, Glenn Gregory M, President, R&D bought 1,000 shares of the company’s stock on Mar 10. The stock was bought for $6,500 at an average price of $6.50. Upon completion of the transaction, the President, R&D now directly owns 14,473 shares in the company, valued at $90311.52. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07, President, R&D Glenn Gregory M bought 2,000 shares of the business’s stock. A total of $14,088 was incurred on buying the stock at an average price of $7.04. This leaves the insider owning 13,473 shares of the company worth $84071.52. Insiders disposed of 24,236 shares of company stock worth roughly $0.15 million over the past 1 year. A total of 7.25% of the company’s stock is owned by insiders.
A candlestick chart of Novavax, Inc. (NASDAQ: NVAX) showed a price of $6.47 on Tuesday morning. During the past 12 months, Novavax, Inc. has had a low of $5.61 and a high of $25.66. The fifty day moving average price for NVAX is $7.18 and a two-hundred day moving average price translates $7.82 for the stock.
The latest earnings results from Novavax, Inc. (NASDAQ: NVAX) was released for Sep, 2023. The company reported revenue of $186.99 million for the quarter, compared to $734.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -74.55 percent.
Novavax, Inc.(NVAX) Company Profile
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.